OctoPlus N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 01 nov 2010 - 13:56

Statutaire naam OctoPlus N.V.

Titel OctoPlus' licensee Biolex presents significant tolerability advantages of Locteron at AASLD conference today

Bericht OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces that its licensee Biolex Therapeutics will present today positive results from two Phase IIb trials further demonstrating the strong anti-viral response and tolerability advantages of the 480 µg dose of Locteron® in the treatment of hepatitis C. In the Phase IIb trials, patients directly reported flu-like adverse events on a daily basis through an electronic patient-reported outcome (ePRO) system, and the results demonstrated a statistically significant reduction in the frequency and severity of flu-like adverse events and reduced use of concomitant (analgesic/antipyretic) medications for patients treated with Locteron compared to patients treated with the PEG-Intron® control. These benefits were already visible in the first week of treatment.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201011010000000010_OctoPlus' licensee Biolex presents significant tolerability advantages of Locteron at AASLD conference today.pdf (opens in a new window)

201011010000000010_OctoPlus' licentiepartner Biolex presenteert vandaag significante veiligheidsvoordelen van Locteron op AASLD congres.pdf (opens in a new window)

Datum laatste update: 23 februari 2026